LEADER 01243nam--2200397---450-
001 990001166460203316
005 20030929133314.0
010   $a3-540-66126-3
035   $a000116646
035   $aUSA01000116646
035   $a(ALEPH)000116646USA01
035   $a000116646
100   $a20030721d2001----km-y0enga50------ba
101 0 $aeng
102   $aDE
105   $aa|||z|||001yy
200 1 $aFibrinolytics and antifibrinolytis$fcontributors F. Bachmann...[et al.]$geditor F. Bachmann
210   $aBerlin [etc.]$cSpringer$dcopyr. 2001
215   $aXXVI, 599 p.$d24 cm
225 2 $aHandbook of experimental pharmacology$v146
410  0$12001$aHandbook of experimental pharmacology
606 0 $aTrombosi$xFarmacoterapia
606 0 $aFibrinolisi
676   $a616.135
702  1$aBACHMANN,$bFedor
801  0$aIT$bsalbc$gISBD
912   $a990001166460203316
951   $a615.1 HAN (146)$b3376 Farm.$c615$d00086255
959   $aBK
969   $aFAR
979   $aMARIA$b10$c20030721$lUSA01$h1029
979   $aMARIA$b10$c20030721$lUSA01$h1032
979   $aPAOLA$b90$c20030929$lUSA01$h1333
979   $aPATRY$b90$c20040406$lUSA01$h1722
996   $aFibrinolytics and antifibrinolytis$9983911
997   $aUNISA